Chronic Lymphocytic Leukemia | Specialty

The chronic lymphocytic leukemia condition center is a comprehensive resource for clinical news on chronic lymphocytic leukemia. Read more at OncLive.

From BTK Inhibitors to CAR T-Cell Therapies: Hematologic Malignancies Landscape Sees an ‘Explosion of New Therapies’

August 7th 2025

Kathleen A. Dorritie, MD, highlights important NCCN guideline updates and research to watch in hematologic malignancies.

FDA Grants Fast Track Designation to Birelentinib for R/R CLL/SLL

August 7th 2025

Birelentinib received fast track designation from the FDA for relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Shift Toward Chemotherapy-Free Approaches Redefines Upfront CLL Treatment Selection

August 6th 2025

Kathleen A. Dorritie, MD, discusses 2 clinical scenario cases to showcase differences in the management of newly diagnosed vs relapsed/refractory CLL.

FDA Approves Tocilizumab Biosimilar for CAR T-Cell Therapy–Induced CRS

August 6th 2025

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

The OncFive: Top Oncology Articles for the Week of 7/27

August 2nd 2025

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

Dr Khan on the Role of Acalabrutinib in the Current CLL Treatment Paradigm

August 1st 2025

Cyrus M. Khan, MD, discusses how acalabrutinib fits into the current treatment paradigm in chronic lymphocytic leukemia.

Pirtobrutinib Demonstrates ORR Noninferiority vs Ibrutinib in BTK Inhibitor–Naive CLL/SLL

July 29th 2025

In BRUIN CLL-314, pirtobrutinib met the primary end point of noninferior ORR vs ibrutinib in both the ITT and pretreated subsets of patients with CLL/SLL.

Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL

July 29th 2025

A supplemental new drug application for all-oral, fixed-duration acalabrutinib plus venetoclax in treatment-naive CLL has been submitted to the FDA.

Novel LYN/BTK Dual Inhibitor Yields Durable Responses in Heavily Pretreated CLL/SLL

July 29th 2025

DZD8586 was active with a tolerable safety profile in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Five Under 5: Top Oncology Videos for the Week of 7/20

July 27th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

Dr Danilov on Considerations in Frontline Treatment Selection for CLL

July 26th 2025

Alexey Danilov, MD, PhD, discusses frontline treatment selection for chronic lymphocytic leukemia.

FDA Approves Generic Ibrutinib Tablets for B-Cell Malignancies

July 24th 2025

The FDA has approved a generic version of ibrutinib tablets for B-cell malignancies.

Dr Khan on the Role of Zanubrutinib in the Current CLL Treatment Paradigm

July 23rd 2025

Cyrus M. Khan, MD, discusses how zanubrutinib fits into the current treatment paradigm in chronic lymphocytic leukemia.

Dr Scarfò on the Future of BGB-16673 in Relapsed/Refractory CLL/SLL

July 21st 2025

Lydia Scarfò, MD, discusses future research directions for BGB-16673 in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Second-Generation BTK Inhibitors Set the Stage for Future Advances in CLL Management

July 17th 2025

Cyrus M. Khan, MD, discusses the role of second-generation BTK inhibitors and their implications for clinical practice in the CLL treatment paradigm.

Dr Munir on a MAIC of Zanubrutinib vs Fixed-Duration Acalabrutinib Plus Venetoclax in CLL

July 11th 2025

Tahla Munir, MBChB, PhD, discusses the rationale for a MAIC of the phase 3 SEQUOIA and AMPLIFY trials in chronic lymphocytic leukemia.

Lisaftoclax Wins Chinese Approval in Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

July 11th 2025

The NMPA has approved lisaftoclax in adult patients with relapsed/refractory CLL/SLL.

BGB-16673 Informs Future Direction for BTK Degraders in Relapsed/Refractory CLL/SLL

July 10th 2025

Lydia Scarfò, MD, details the early efficacy and safety profile of BTK degrader BGB-16673 for the treatment of patients with relapsed/refractory CLL/SLL.

Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Long-Term Efficacy in Untreated CLL/SLL

July 9th 2025

Fixed-duration ibrutinib plus venetoclax was effective with nearly 70 months of follow-up in patients with untreated CLL/SLL.

Dr Scarfò on the Rationale for Evaluating BGB-16673 in Relapsed/Refractory CLL

June 30th 2025

Lydia Scarfò, MD, explains the rationale for evaluating the BTK degrader BGB-16673 for patients with relapsed/refractory CLL.